ArticleLeukemia2010

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

P Chevallier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.